This site is intended for US healthcare professionals.

Activity in predefined subgroups: exploratory PFS analysis1

Activity in predefined subgroups: exploratory PFS analysis1

Watch Dr. Barata discuss the relevance of the PFS subgroup analysis in TIVO-3 based on prior therapies.

See the Video

Prior checkpoint inhibitor and prior VEGFR TKI

Graph showing PFS for FOTIVDA (5.5 months) and sorafenib (3.7 months) with HR=0.57 in patients with two prior treatments.

Two prior VEGFR TKIs

Graph showing PFS for FOTIVDA (5.5 months) and sorafenib (3.7 months) with HR=0.57 in patients with two prior VEGFR TKIs.

Prior VEGFR TKI and other*

Table comparing FOTIVDA and sorafenib in patients receiving VEGFR TKI and other therapy.

*K-M curve was not published for this data.

Discover the durability of response.

View DOR

Learn about dosing.

See More

Reach out to an AVEO
Oncology Account
Manager.

Get in Touch

CI=confidence interval; HR=hazard ratio; K-M=Kaplan-Meier; mPFS=median progression-free survival; PFS=progression-free survival; TKI=tyrosine kinase inhibitor; VEGFR=vascular endothelial growth factor receptor.

Reference: 1. Pal SK, Escudier B, Atkins MB, et al. TIVO-3: Final OS analysis of a randomized, controlled, multi-center, open-label phase 3 study to compare tivozanib to sorafenib in subjects with metastatic renal cell carcinoma (RCC). Poster presented at ASCO, May 2020.